{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:32:24Z","timestamp":1794933144530,"version":"4.9.1"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82025015"],"award-info":[{"award-number":["82025015"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32230038"],"award-info":[{"award-number":["32230038"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Type I interferons have been well recognized for their roles in various types of immune cells during tumor immunotherapy. However, their direct effects on tumor cells are less understood. Oxidative phosphorylation is typically latent in tumor cells. Whether oxidative phosphorylation can be targeted for immunotherapy remains unclear. Here, we find that tumor cell responsiveness to type I, but not type II interferons, is essential for CD47-SIRP\u03b1 blockade immunotherapy in female mice. Mechanistically, type I interferons directly reprogram tumor cell metabolism by activating oxidative phosphorylation for ATP production in an ISG15-dependent manner. ATP extracellular release is also promoted by type I interferons due to enhanced secretory autophagy. Functionally, tumor cells with genetic deficiency in oxidative phosphorylation or autophagy are resistant to CD47-SIRP\u03b1 blockade. ATP released upon CD47-SIRP\u03b1 blockade is required for antitumor T cell response induction via P2X7 receptor-mediated dendritic cell activation. Based on this mechanism, combinations with inhibitors of ATP-degrading ectoenzymes, CD39 and CD73, are designed and show synergistic antitumor effects with CD47-SIRP\u03b1 blockade. Together, these data reveal an important role of type I interferons on tumor cell metabolic reprograming for tumor immunotherapy and provide rational strategies harnessing this mechanism for enhanced efficacy of CD47-SIRP\u03b1 blockade.<\/jats:p>","DOI":"10.1038\/s41467-024-50136-z","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T19:03:08Z","timestamp":1720551788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Metabolic reprograming mediated by tumor cell-intrinsic type I IFN signaling is required for CD47-SIRP\u03b1 blockade efficacy"],"prefix":"10.1038","volume":"15","author":[{"given":"Hang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjie","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2482-5475","authenticated-orcid":false,"given":"Hua","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8441-6617","authenticated-orcid":false,"given":"Yang-Xin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2001-2669","authenticated-orcid":false,"given":"Mingzhao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"50136_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1146\/annurev-pathol-031920-093932","volume":"16","author":"GM Boukhaled","year":"2021","unstructured":"Boukhaled, G. M., Harding, S. & Brooks, D. G. Opposing roles of type I interferons in cancer immunity. Annu. Rev. Pathol. 16, 167\u2013198 (2021).","journal-title":"Annu. Rev. Pathol."},{"key":"50136_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nri3845","volume":"15","author":"L Zitvogel","year":"2015","unstructured":"Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J. & Kroemer, G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15, 405\u2013414 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"50136_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrc.2016.14","volume":"16","author":"BS Parker","year":"2016","unstructured":"Parker, B. S., Rautela, J. & Hertzog, P. J. Antitumour actions of interferons: implications for cancer therapy. Nat. Rev. Cancer 16, 131\u2013144 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"50136_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/imr.13272","volume":"321","author":"P Holicek","year":"2024","unstructured":"Holicek, P. et al. Type I interferon and cancer. Immunol. Rev. 321, 115\u2013127 (2024).","journal-title":"Immunol. Rev."},{"key":"50136_CR5","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/nm.3708","volume":"20","author":"A Sistigu","year":"2014","unstructured":"Sistigu, A. et al. Cancer cell\u2013autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 20, 1301\u20131309 (2014).","journal-title":"Nat. Med."},{"key":"50136_CR6","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3389\/fimmu.2020.00976","volume":"11","author":"N Karin","year":"2020","unstructured":"Karin, N. CXCR3 ligands in cancer and autoimmunity, chemoattraction of effector T cells, and beyond. Front. Immunol. 11, 976 (2020).","journal-title":"Front. Immunol."},{"key":"50136_CR7","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41568-019-0183-z","volume":"19","author":"M Feng","year":"2019","unstructured":"Feng, M. et al. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat. Rev. Cancer 19, 568\u2013586 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"50136_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41392-023-01365-z","volume":"8","author":"Liu Ye","year":"2023","unstructured":"Liu Ye et al. Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduct. Target. Ther. 8, 104 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"50136_CR9","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti, R. et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286\u2013299 (2009).","journal-title":"Cell"},{"key":"50136_CR10","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","volume":"142","author":"MP Chao","year":"2010","unstructured":"Chao, M. P. et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142, 699\u2013713 (2010).","journal-title":"Cell"},{"key":"50136_CR11","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1073\/pnas.1121623109","volume":"109","author":"SB Willingham","year":"2012","unstructured":"Willingham, S. B. et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl. Acad. Sci. 109, 6662\u20136667 (2012).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"50136_CR12","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1158\/0008-5472.CAN-10-2238","volume":"71","author":"MP Chao","year":"2011","unstructured":"Chao, M. P. et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res. 71, 1374\u20131384 (2011).","journal-title":"Cancer Res."},{"key":"50136_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100070","volume":"13","author":"R Maute","year":"2022","unstructured":"Maute, R., Xu, J. & Weissman, I. L. CD47\u2013SIRP\u03b1-targeted therapeutics: status and prospects. Immuno-Oncol. Technol. 13, 100070 (2022).","journal-title":"Immuno-Oncol. Technol."},{"key":"50136_CR14","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","volume":"52","author":"MEW Logtenberg","year":"2020","unstructured":"Logtenberg, M. E. W., Scheeren, F. A. & Schumacher, T. N. The CD47-SIRP\u03b1 immune checkpoint. Immunity 52, 742\u2013752 (2020).","journal-title":"Immunity"},{"key":"50136_CR15","first-page":"80","volume":"3","author":"AR Jalil","year":"2020","unstructured":"Jalil, A. R., Andrechak, J. C. & Discher, D. E. Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRP\u03b1 structure-function. Antib. Ther. 3, 80\u201394 (2020).","journal-title":"Antib. Ther."},{"key":"50136_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1584","volume":"14","author":"JS Isenberg","year":"2024","unstructured":"Isenberg, J. S. & Montero, E. Tolerating CD47. Clin. Transl. Med. 14, e1584 (2024).","journal-title":"Clin. Transl. Med."},{"key":"50136_CR17","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/nm.3931","volume":"21","author":"X Liu","year":"2015","unstructured":"Liu, X. et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat. Med. 21, 1209\u20131215 (2015).","journal-title":"Nat. Med."},{"key":"50136_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrc3038","volume":"11","author":"WH Koppenol","year":"2011","unstructured":"Koppenol, W. H., Bounds, P. L. & Dang, C. V. Otto Warburg\u2019s contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 11, 325\u2013337 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"50136_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41422-019-0181-4","volume":"29","author":"S Rao","year":"2019","unstructured":"Rao, S. et al. AIF-regulated oxidative phosphorylation supports lung cancer development. Cell Res. 29, 579\u2013591 (2019).","journal-title":"Cell Res."},{"key":"50136_CR20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ccr.2012.11.020","volume":"23","author":"F Vazquez","year":"2013","unstructured":"Vazquez, F. et al. PGC1\u03b1 expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 23, 287\u2013301 (2013).","journal-title":"Cancer Cell"},{"key":"50136_CR21","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ccr.2013.02.003","volume":"23","author":"R Haq","year":"2013","unstructured":"Haq, R. et al. Oncogenic BRAF regulates oxidative metabolism via PGC1\u03b1 and MITF. Cancer Cell 23, 302\u2013315 (2013).","journal-title":"Cancer Cell"},{"key":"50136_CR22","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1101\/gad.188292.112","volume":"26","author":"M Janiszewska","year":"2012","unstructured":"Janiszewska, M. et al. Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes Dev. 26, 1926\u20131944 (2012).","journal-title":"Genes Dev."},{"key":"50136_CR23","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1126\/science.1193494","volume":"330","author":"AJ Levine","year":"2010","unstructured":"Levine, A. J. & Puzio-Kuter, A. M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330, 1340\u20131344 (2010).","journal-title":"Science"},{"key":"50136_CR24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ccr.2006.04.023","volume":"9","author":"VR Fantin","year":"2006","unstructured":"Fantin, V. R., St-Pierre, J. & Leder, P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9, 425\u2013434 (2006).","journal-title":"Cancer Cell"},{"key":"50136_CR25","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.cell.2015.12.034","volume":"164","author":"ChristopherT Hensley","year":"2016","unstructured":"Hensley, ChristopherT. et al. Metabolic heterogeneity in human lung tumors. Cell 164, 681\u2013694 (2016).","journal-title":"Cell"},{"key":"50136_CR26","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1073\/pnas.1816391116","volume":"116","author":"D Jia","year":"2019","unstructured":"Jia, D. et al. Elucidating cancer metabolic plasticity by coupling gene regulation with metabolic pathways. Proc. Natl. Acad. Sci. USA 116, 3909\u20133918 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"50136_CR27","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41416-019-0542-2","volume":"121","author":"A El-Kenawi","year":"2019","unstructured":"El-Kenawi, A. et al. Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer. Br. J. Cancer 121, 556\u2013566 (2019).","journal-title":"Br. J. Cancer"},{"key":"50136_CR28","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","volume":"24","author":"A Brand","year":"2016","unstructured":"Brand, A. et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 24, 657\u2013671 (2016).","journal-title":"Cell Metab."},{"key":"50136_CR29","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.4049\/jimmunol.1202702","volume":"191","author":"Z Husain","year":"2013","unstructured":"Husain, Z., Huang, Y., Seth, P. & Sukhatme, V. P. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J. Immunol. (Baltim., Md: 1950) 191, 1486\u20131495 (2013).","journal-title":"J. Immunol. (Baltim., Md: 1950)"},{"key":"50136_CR30","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cell.2019.05.003","volume":"178","author":"W Zhang","year":"2019","unstructured":"Zhang, W. et al. Lactate is a natural suppressor of RLR signaling by targeting MAVS. Cell 178, 176\u2013189.e115 (2019).","journal-title":"Cell"},{"key":"50136_CR31","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature13490","volume":"513","author":"OR Colegio","year":"2014","unstructured":"Colegio, O. R. et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513, 559\u2013563 (2014).","journal-title":"Nature"},{"key":"50136_CR32","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-019-1678-1","volume":"574","author":"D Zhang","year":"2019","unstructured":"Zhang, D. et al. Metabolic regulation of gene expression by histone lactylation. Nature 574, 575\u2013580 (2019).","journal-title":"Nature"},{"key":"50136_CR33","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","volume":"79","author":"DC Hinshaw","year":"2019","unstructured":"Hinshaw, D. C. & Shevde, L. A. The tumor microenvironment innately modulates cancer progression. Cancer Res. 79, 4557\u20134566 (2019).","journal-title":"Cancer Res."},{"key":"50136_CR34","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","volume":"109","author":"K Fischer","year":"2007","unstructured":"Fischer, K. et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109, 3812\u20133819 (2007).","journal-title":"Blood"},{"key":"50136_CR35","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021108130","volume":"40","author":"O Kepp","year":"2021","unstructured":"Kepp, O. et al. ATP and cancer immunosurveillance. EMBO J. 40, e108130 (2021).","journal-title":"EMBO J."},{"key":"50136_CR36","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.3390\/cells9112496","volume":"9","author":"V Vultaggio-Poma","year":"2020","unstructured":"Vultaggio-Poma, V., Sarti, A. C. & Di Virgilio, F. Extracellular ATP: a feasible target for cancer therapy. Cells 9, 2496 (2020).","journal-title":"Cells"},{"key":"50136_CR37","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.3390\/cancers12071748","volume":"12","author":"A Kotsafti","year":"2020","unstructured":"Kotsafti, A., Scarpa, M., Castagliuolo, I. & Scarpa, M. Reactive oxygen species and antitumor immunity\u2014from surveillance to evasion. Cancers 12, 1748 (2020).","journal-title":"Cancers"},{"key":"50136_CR38","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3390\/antiox11050853","volume":"11","author":"R Liu","year":"2022","unstructured":"Liu, R. et al. Oxidative stress in cancer immunotherapy: molecular mechanisms and potential applications. Antioxidants 11, 853 (2022).","journal-title":"Antioxidants"},{"key":"50136_CR39","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/cr.2009.69","volume":"19","author":"J Lu","year":"2009","unstructured":"Lu, J., Sharma, L. K. & Bai, Y. Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis. Cell Res. 19, 802\u2013815 (2009).","journal-title":"Cell Res."},{"key":"50136_CR40","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.freeradbiomed.2016.04.025","volume":"100","author":"M Sciacovelli","year":"2016","unstructured":"Sciacovelli, M. & Frezza, C. Oncometabolites: unconventional triggers of oncogenic signalling cascades. Free Radic. Biol. Med. 100, 175\u2013181 (2016).","journal-title":"Free Radic. Biol. Med."},{"key":"50136_CR41","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1002\/ijc.29080","volume":"135","author":"A Morin","year":"2014","unstructured":"Morin, A., Letouz\u00e9, E., Gimenez-Roqueplo, A. P. & Favier, J. Oncometabolites-driven tumorigenesis: from genetics to targeted therapy. Int. J. Cancer 135, 2237\u20132248 (2014).","journal-title":"Int. J. Cancer"},{"key":"50136_CR42","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.celrep.2014.06.043","volume":"8","author":"PE Porporato","year":"2014","unstructured":"Porporato, P. E. et al. A mitochondrial switch promotes tumor metastasis. Cell Rep. 8, 754\u2013766 (2014).","journal-title":"Cell Rep."},{"key":"50136_CR43","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3390\/jcm8070967","volume":"8","author":"TM Thomson","year":"2019","unstructured":"Thomson, T. M., Balcells, C. & Cascante, M. Metabolic plasticity and epithelial-mesenchymal transition. J. Clin. Med. 8, 967 (2019).","journal-title":"J. Clin. Med."},{"key":"50136_CR44","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3389\/fonc.2018.00170","volume":"8","author":"J Hlouschek","year":"2018","unstructured":"Hlouschek, J., Hansel, C., Jendrossek, V. & Matschke, J. The mitochondrial citrate carrier (SLC25A1) sustains redox homeostasis and mitochondrial metabolism supporting radioresistance of cancer cells with tolerance to cycling severe hypoxia. Front. Oncol. 8, 170 (2018).","journal-title":"Front. Oncol."},{"key":"50136_CR45","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s41418-018-0101-z","volume":"25","author":"HR Fernandez","year":"2018","unstructured":"Fernandez, H. R. et al. The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. Cell Death Differ. 25, 1239\u20131258 (2018).","journal-title":"Cell Death Differ."},{"key":"50136_CR46","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/nm.4399","volume":"23","author":"EM Kuntz","year":"2017","unstructured":"Kuntz, E. M. et al. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. Nat. Med. 23, 1234\u20131240 (2017).","journal-title":"Nat. Med."},{"key":"50136_CR47","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1158\/1078-0432.CCR-17-3070","volume":"24","author":"TM Ashton","year":"2018","unstructured":"Ashton, T. M., McKenna, W. G., Kunz-Schughart, L. A. & Higgins, G. S. Oxidative phosphorylation as an emerging target in cancer therapy. Clin. Cancer Res. 24, 2482\u20132490 (2018).","journal-title":"Clin. Cancer Res."},{"key":"50136_CR48","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.molmed.2019.06.009","volume":"26","author":"KG Roth","year":"2020","unstructured":"Roth, K. G., Mambetsariev, I., Kulkarni, P. & Salgia, R. The mitochondrion as an emerging therapeutic target in cancer. Trends Mol. Med. 26, 119\u2013134 (2020).","journal-title":"Trends Mol. Med."},{"key":"50136_CR49","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1126\/science.1238856","volume":"341","author":"K Weiskopf","year":"2013","unstructured":"Weiskopf, K. et al. Engineered SIRP\u03b1 variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341, 88\u201391 (2013).","journal-title":"Science"},{"key":"50136_CR50","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/j.celrep.2018.07.062","volume":"24","author":"X Liu","year":"2018","unstructured":"Liu, X. et al. Dual targeting of innate and adaptive checkpoints on tumor cells limits immune evasion. Cell Rep. 24, 2101\u20132111 (2018).","journal-title":"Cell Rep."},{"key":"50136_CR51","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51\u201372 (2013).","journal-title":"Annu. Rev. Immunol."},{"key":"50136_CR52","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko, D. V. et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12, 860\u2013875 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"50136_CR53","doi-asserted-by":"publisher","first-page":"12820","DOI":"10.1074\/jbc.RA118.003737","volume":"293","author":"H Huo","year":"2018","unstructured":"Huo, H., Fryatt, A. G., Farmer, L. K., Schmid, R. & Evans, R. J. Mapping the binding site of the P2X receptor antagonist PPADS reveals the importance of orthosteric site charge and the cysteine-rich head region. J. Biol. Chem. 293, 12820\u201312831 (2018).","journal-title":"J. Biol. Chem."},{"key":"50136_CR54","doi-asserted-by":"publisher","first-page":"633861","DOI":"10.3389\/fphar.2020.633861","volume":"11","author":"A Martire","year":"2021","unstructured":"Martire, A., Pepponi, R., Liguori, F., Volont\u00e9, C. & Popoli, P. P2X7 receptor agonist 2\u2032(3\u2032)-O-(4-Benzoylbenzoyl)ATP differently modulates cell viability and corticostriatal synaptic transmission in experimental models of Huntington\u2019s disease. Front. Pharmacol. 11, 633861 (2021).","journal-title":"Front. Pharmacol."},{"key":"50136_CR55","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.immuni.2017.07.016","volume":"47","author":"MM Xu","year":"2017","unstructured":"Xu, M. M. et al. Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein alpha signaling. Immunity 47, 363\u2013373 e365 (2017).","journal-title":"Immunity"},{"key":"50136_CR56","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0005-2728(92)90001-I","volume":"1140","author":"IM Fearnley","year":"1992","unstructured":"Fearnley, I. M. & Walker, J. E. Conservation of sequences of subunits of mitochondrial complex I and their relationships with other proteins. Biochim. Biophys. Acta 1140, 105\u2013134 (1992).","journal-title":"Biochim. Biophys. Acta"},{"key":"50136_CR57","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0005-2728(03)00059-8","volume":"1604","author":"J Hirst","year":"2003","unstructured":"Hirst, J., Carroll, J., Fearnley, I. M., Shannon, R. J. & Walker, J. E. The nuclear encoded subunits of complex I from bovine heart mitochondria. Biochim. Biophys. Acta 1604, 135\u2013150 (2003).","journal-title":"Biochim. Biophys. Acta"},{"key":"50136_CR58","doi-asserted-by":"publisher","first-page":"e1006651","DOI":"10.1371\/journal.ppat.1006651","volume":"13","author":"S Baldanta","year":"2017","unstructured":"Baldanta, S. et al. ISG15 governs mitochondrial function in macrophages following vaccinia virus infection. PLoS Pathog. 13, e1006651 (2017).","journal-title":"PLoS Pathog."},{"key":"50136_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16395-2","volume":"11","author":"S Alcal\u00e1","year":"2020","unstructured":"Alcal\u00e1, S. et al. ISG15 and ISGylation is required for pancreatic cancer stem cell mitophagy and metabolic plasticity. Nat. Commun. 11, 2682 (2020).","journal-title":"Nat. Commun."},{"key":"50136_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.931","volume":"12","author":"Waqas SF-u-H","year":"2022","unstructured":"Waqas SF-u-H et al. ISG15 deficiency features a complex cellular phenotype that responds to treatment with itaconate and derivatives. Clin. Transl. Med. 12, e931 (2022).","journal-title":"Clin. Transl. Med."},{"key":"50136_CR61","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1126\/science.1208347","volume":"334","author":"M Michaud","year":"2011","unstructured":"Michaud, M. et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334, 1573\u20131577 (2011).","journal-title":"Science"},{"key":"50136_CR62","doi-asserted-by":"publisher","first-page":"683","DOI":"10.4161\/auto.23921","volume":"9","author":"H Schmeisser","year":"2013","unstructured":"Schmeisser, H. et al. Type I interferons induce autophagy in certain human cancer cell lines. Autophagy 9, 683\u2013696 (2013).","journal-title":"Autophagy"},{"key":"50136_CR63","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1080\/15548627.2020.1812218","volume":"17","author":"DS Oh","year":"2021","unstructured":"Oh, D. S., Park, J. H., Jung, H. E., Kim, H.-J. & Lee, H. K. Autophagic protein ATG5 controls antiviral immunity via glycolytic reprogramming of dendritic cells against respiratory syncytial virus infection. Autophagy 17, 2111\u20132127 (2021).","journal-title":"Autophagy"},{"key":"50136_CR64","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-3-030-35727-6_7","volume":"1225","author":"R Kang","year":"2020","unstructured":"Kang, R., Zeh, H., Lotze, M. & Tang, D. The multifaceted effects of autophagy on the tumor microenvironment. Adv. Exp. Med. Biol. 1225, 99\u2013114 (2020).","journal-title":"Adv. Exp. Med. Biol."},{"key":"50136_CR65","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","volume":"581","author":"K Yamamoto","year":"2020","unstructured":"Yamamoto, K. et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature 581, 100\u2013105 (2020).","journal-title":"Nature"},{"key":"50136_CR66","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/med.21531","volume":"39","author":"H Folkerts","year":"2019","unstructured":"Folkerts, H., Hilgendorf, S., Vellenga, E., Bremer, E. & Wiersma, V. R. The multifaceted role of autophagy in cancer and the microenvironment. Med. Res. Rev. 39, 517\u2013560 (2019).","journal-title":"Med. Res. Rev."},{"key":"50136_CR67","doi-asserted-by":"publisher","first-page":"eaau8943","DOI":"10.1126\/sciimmunol.aau8943","volume":"4","author":"S Heidegger","year":"2019","unstructured":"Heidegger, S. et al. RIG-I activation is critical for responsiveness to checkpoint blockade. Sci. Immunol. 4, eaau8943 (2019).","journal-title":"Sci. Immunol."},{"key":"50136_CR68","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1158\/0008-5472.CAN-09-3566","volume":"70","author":"L Aymeric","year":"2010","unstructured":"Aymeric, L. et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res. 70, 855\u2013858 (2010).","journal-title":"Cancer Res."},{"key":"50136_CR69","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/imr.12528","volume":"276","author":"B Allard","year":"2017","unstructured":"Allard, B., Longhi, M. S., Robson, S. C. & Stagg, J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol. Rev. 276, 121\u2013144 (2017).","journal-title":"Immunol. Rev."},{"key":"50136_CR70","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nrc.2017.110","volume":"17","author":"D Vijayan","year":"2017","unstructured":"Vijayan, D., Young, A., Teng, M. W. L. & Smyth, M. J. Targeting immunosuppressive adenosine in cancer. Nat. Rev. Cancer 17, 765 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"50136_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0360-8","volume":"6","author":"RD Leone","year":"2018","unstructured":"Leone, R. D. & Emens, L. A. Targeting adenosine for cancer immunotherapy. J. Immunother. Cancer 6, 57 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"50136_CR72","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi, S., Yuan, R. & Engleman, E. G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu. Rev. Pathol. 16, 223\u2013249 (2021).","journal-title":"Annu. Rev. Pathol."},{"key":"50136_CR73","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi, A. & Ribas, A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 20, 25\u201339 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"50136_CR74","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/j.devcel.2022.06.008","volume":"57","author":"DG Kirova","year":"2022","unstructured":"Kirova, D. G. et al. A ROS-dependent mechanism promotes CDK2 phosphorylation to drive progression through S phase. Dev. Cell 57, 1712\u20131727.e1719 (2022).","journal-title":"Dev. Cell"},{"key":"50136_CR75","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/jcb.25074","volume":"116","author":"S Movafagh","year":"2015","unstructured":"Movafagh, S., Crook, S. & Vo, K. Regulation of hypoxia-inducible factor-1a by reactive oxygen species: new developments in an old debate. J. Cell. Biochem. 116, 696\u2013703 (2015).","journal-title":"J. Cell. Biochem."},{"key":"50136_CR76","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1128\/MCB.00971-15","volume":"36","author":"H Satooka","year":"2016","unstructured":"Satooka, H. & Hara-Chikuma, M. Aquaporin-3 controls breast cancer cell migration by regulating hydrogen peroxide transport and its downstream cell signaling. Mol. Cell. Biol. 36, 1206\u20131218 (2016).","journal-title":"Mol. Cell. Biol."},{"key":"50136_CR77","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nature01680","volume":"423","author":"A Salmeen","year":"2003","unstructured":"Salmeen, A. et al. Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate. Nature 423, 769\u2013773 (2003).","journal-title":"Nature"},{"key":"50136_CR78","doi-asserted-by":"publisher","first-page":"20336","DOI":"10.1074\/jbc.M111899200","volume":"277","author":"SR Lee","year":"2002","unstructured":"Lee, S. R. et al. Reversible inactivation of the tumor suppressor PTEN by H2O2. J. Biol. Chem. 277, 20336\u201320342 (2002).","journal-title":"J. Biol. Chem."},{"key":"50136_CR79","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1128\/MCB.20.6.2198-2208.2000","volume":"20","author":"H Liu","year":"2000","unstructured":"Liu, H., Nishitoh, H., Ichijo, H. & Kyriakis, J. M. Activation of apoptosis signal-regulating kinase 1 (ASK1) by tumor necrosis factor receptor-associated factor 2 requires prior dissociation of the ASK1 inhibitor thioredoxin. Mol. Cell. Biol. 20, 2198\u20132208 (2000).","journal-title":"Mol. Cell. Biol."},{"key":"50136_CR80","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1126\/science.1144318","volume":"317","author":"JR Burgoyne","year":"2007","unstructured":"Burgoyne, J. R. et al. Cysteine redox sensor in PKGIa enables oxidant-induced activation. Science 317, 1393\u20131397 (2007).","journal-title":"Science"},{"key":"50136_CR81","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.cell.2004.12.041","volume":"120","author":"H Kamata","year":"2005","unstructured":"Kamata, H. et al. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120, 649\u2013661 (2005).","journal-title":"Cell"},{"key":"50136_CR82","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nchembio727","volume":"1","author":"VE Kagan","year":"2005","unstructured":"Kagan, V. E. et al. Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors. Nat. Chem. Biol. 1, 223\u2013232 (2005).","journal-title":"Nat. Chem. Biol."},{"key":"50136_CR83","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/cr.2009.19","volume":"19","author":"Y Zuo","year":"2009","unstructured":"Zuo, Y. et al. Oxidative modification of caspase-9 facilitates its activation via disulfide-mediated interaction with Apaf-1. Cell Res. 19, 449\u2013457 (2009).","journal-title":"Cell Res."},{"key":"50136_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14329","volume":"8","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. et al. RIP1 autophosphorylation is promoted by mitochondrial ROS and is essential for RIP3 recruitment into necrosome. Nat. Commun. 8, 14329 (2017).","journal-title":"Nat. Commun."},{"key":"50136_CR85","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/cdd.2015.158","volume":"23","author":"Y Xie","year":"2016","unstructured":"Xie, Y. et al. Ferroptosis: process and function. Cell Death Differ. 23, 369\u2013379 (2016).","journal-title":"Cell Death Differ."},{"key":"50136_CR86","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","volume":"167","author":"J Gao","year":"2016","unstructured":"Gao, J. et al. Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167, 397\u2013404 e399 (2016).","journal-title":"Cell"},{"key":"50136_CR87","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature23270","volume":"547","author":"RT Manguso","year":"2017","unstructured":"Manguso, R. T. et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547, 413\u2013418 (2017).","journal-title":"Nature"},{"key":"50136_CR88","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819\u2013829 (2016).","journal-title":"N. Engl. J. Med."},{"key":"50136_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50136-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50136-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50136-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T20:19:40Z","timestamp":1720556380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50136-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["50136"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-50136-z","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"10 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5759"}}